VCI Global (NASDAQ: VCIG) limits 2026 stock sale to 81,500 shares

Rhea-AI Filing Summary

VCI Global Ltd (VCIG) filed a prospectus supplement that amends its March 6, 2026 prospectus supplement to significantly narrow the securities covered. The earlier document related to an institutional offering of ordinary shares, pre-funded warrants, and two series of common warrants under a securities purchase agreement with a single investor.

The new supplement limits coverage to 81,500 Ordinary Shares, including shares issued upon exercise of pre-funded warrants. All of these ordinary shares have already been sold and issued as of the date of this supplement, so the document mainly aligns the registration disclosure with the actual issuance.

The share counts in the supplement reflect a 1-for-60 reverse stock split effective February 27, 2026 and a 1-for-15 reverse stock split effective August 24, 2026. VCIG’s ordinary shares trade on Nasdaq under the symbol VCIG; on August 21, 2026, the last reported sale price was $0.2129 per share. The company states it qualifies as an “emerging growth company” and a foreign private issuer, which allows reduced U.S. reporting requirements.

Key Figures

Ordinary Shares covered by current supplement: 81,500 Ordinary Shares Ordinary Shares in original March 2026 offering: 305,623 Ordinary Shares Pre-Funded Warrants original size: 305,623 Ordinary Shares +5 more

8 metrics

Ordinary Shares covered by current supplement 81,500 Ordinary Shares Shares issued and sold, including upon exercise of Pre-Funded Warrants

Ordinary Shares in original March 2026 offering 305,623 Ordinary Shares Part of original offering before reduction by this supplement

Pre-Funded Warrants original size 305,623 Ordinary Shares Ordinary Shares underlying Pre-Funded Warrants in March 2026 offering

Common A Warrants original size 611,247 Ordinary Shares Ordinary Shares underlying Common A Warrants in March 2026 offering

Common B Warrants original size 611,247 Ordinary Shares Ordinary Shares underlying Common B Warrants in March 2026 offering

Reverse stock split ratio (February 27, 2026) 1-for-60 Reverse stock split of Ordinary Shares

Reverse stock split ratio (August 24, 2026) 1-for-15 Reverse stock split of Ordinary Shares

Nasdaq last reported sale price $0.2129 per share Ordinary Shares on August 21, 2026

Key Terms

Prospectus Supplement, Pre-Funded Warrants, Common Warrants, reverse stock split, +2 more

6 terms

Prospectus Supplement regulatory

"This prospectus supplement (the “Prospectus Supplement”) amends and supplements"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Pre-Funded Warrants financial

"pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 305,623"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Common Warrants financial

"Common B Warrants (the “Common B Warrants” and together with the Common"

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

reverse stock split financial

"gives effect to (i) the 1-for-60 reverse stock split of the Company's"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

emerging growth company regulatory

"We are an “emerging growth company,” as that term is defined"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

foreign private issuer regulatory

"Implications of Our Foreign Private Issuers Status” for additional information"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Offering Details

shelf

Offering

Offering Type shelf

FAQ

What does VCI Global Ltd (VCIG) change in this August 2026 prospectus supplement?

The supplement reduces the March 6, 2026 prospectus supplement to cover only 81,500 Ordinary Shares, including shares issued upon exercise of pre-funded warrants. All of these shares have already been sold and issued as of the date of the supplement.

How many VCI Global Ltd (VCIG) shares are now covered versus the original March 2026 offering?

The original March 2026 supplement related to 305,623 Ordinary Shares, pre-funded warrants for 305,623 shares, and common warrants for 611,247+611,247 shares. The updated supplement now covers only 81,500 Ordinary Shares, including those from exercised pre-funded warrants.

Have the 81,500 VCI Global Ltd (VCIG) shares in this supplement been sold?

Yes. The company states that all 81,500 Ordinary Shares covered by the supplement, including those issued upon exercise of pre-funded warrants, have been sold and issued as of the date of the prospectus supplement.

What reverse stock splits has VCI Global Ltd (VCIG) implemented in 2026?

The share numbers in the document give effect to a 1-for-60 reverse stock split of ordinary shares effective February 27, 2026, and a 1-for-15 reverse stock split of ordinary shares effective August 24, 2026.

What is the recent Nasdaq trading price mentioned for VCI Global Ltd (VCIG)?

The company reports that on August 21, 2026, the last reported sale price of its ordinary shares on the Nasdaq Capital Market was $0.2129 per share.

What regulatory status does VCI Global Ltd (VCIG) claim in this supplement?

VCI Global Ltd states it is an “emerging growth company” under U.S. federal securities laws and also notes implications of its foreign private issuer status, which allow it to follow certain reduced public company reporting requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 06:01 AM Accepted by SEC EDGAR 08/24/2026 - 05:45 PM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(5)

Registration Statement No. 333-279521

Prospectus Supplement

(To Prospectus dated May 28, 2024)

 

81,500 Ordinary Shares

This prospectus supplement (the “Prospectus Supplement”) amends and supplements the prospectus supplement dated March 6, 2026 (the “March 2026 Prospectus Supplement”) to reduce the securities covered thereby. The March 2026 Prospectus Supplement related to the offering of (i) 305,623 of our ordinary shares, no par value per share (the “Ordinary Shares”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 305,623 of our Ordinary Shares, (iii) Common A Warrants (the “Common A Warrants”) to purchase 611,247 Ordinary Shares and (iv) Common B Warrants (the “Common B Warrants” and together with the Common A Warrants, the “Common Warrants”) to purchase 611,247 Ordinary Shares, directly to a single institutional investor (the “Investor”) pursuant to a securities purchase agreement dated March 6, 2026 (the “Securities Purchase Agreement”).

We are filing this Prospectus Supplement to reduce the March 2026 Prospectus Supplement to cover only 81,500 Ordinary Shares issued (including upon exercise of Pre-Funded Warrants). All the Ordinary Shares covered by this Prospectus Supplement have been sold and issued as of the date of this Prospectus Supplement.

The number of Ordinary Shares referenced in this Prospectus Supplement gives effect to (i) the 1-for-60 reverse stock split of the Company's Ordinary Shares effected on February 27, 2026 and (ii) the 1-for-15 reverse stock split of the Company's Ordinary Shares effected on August 24, 2026.

Our Ordinary Shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the symbols “VCIG.” On August 21, 2026, the last reported sale price of our ordinary shares on Nasdaq was $0.2129 per share.

Investing in our securities involves a high degree of risk. See “Risk Factors” section beginning on page S-11 of the March 2026 Prospectus Supplement.

We are an “emerging growth company,” as that term is defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements and may elect to do so in future filings. See the sections entitled “Prospectus Supplement Summary—Implications of Being an Emerging Growth Company” and “Prospectus Supplement Summary—Implications of Our Foreign Private Issuers Status” for additional information.

Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is August 24, 2026